Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jana Mihályová, Katarína Hradská, Tomáš Jelínek, Benjamin Motais, Piotr Celichowski, Roman Hájek
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immunotherapy bispecific antibodies antibody-drug conjugates brentuximab vedotin polatuzumab vedotin mosenutuzumab Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/007347c5ac0b458cb176804d58895469
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:007347c5ac0b458cb176804d58895469
record_format	dspace
spelling	oai:doaj.org-article:007347c5ac0b458cb176804d588954692021-11-11T16:55:57ZPromising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders10.3390/ijms2221114701422-00671661-6596https://doaj.org/article/007347c5ac0b458cb176804d588954692021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11470https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.Jana MihályováKatarína HradskáTomáš JelínekBenjamin MotaisPiotr CelichowskiRoman HájekMDPI AGarticleimmunotherapybispecific antibodiesantibody-drug conjugatesbrentuximab vedotinpolatuzumab vedotinmosenutuzumabBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11470, p 11470 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy bispecific antibodies antibody-drug conjugates brentuximab vedotin polatuzumab vedotin mosenutuzumab Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	immunotherapy bispecific antibodies antibody-drug conjugates brentuximab vedotin polatuzumab vedotin mosenutuzumab Biology (General) QH301-705.5 Chemistry QD1-999 Jana Mihályová Katarína Hradská Tomáš Jelínek Benjamin Motais Piotr Celichowski Roman Hájek Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
description	Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.
format	article
author	Jana Mihályová Katarína Hradská Tomáš Jelínek Benjamin Motais Piotr Celichowski Roman Hájek
author_facet	Jana Mihályová Katarína Hradská Tomáš Jelínek Benjamin Motais Piotr Celichowski Roman Hájek
author_sort	Jana Mihályová
title	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
title_short	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
title_full	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
title_fullStr	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
title_full_unstemmed	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
title_sort	promising immunotherapeutic modalities for b-cell lymphoproliferative disorders
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/007347c5ac0b458cb176804d58895469
work_keys_str_mv	AT janamihalyova promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders AT katarinahradska promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders AT tomasjelinek promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders AT benjaminmotais promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders AT piotrcelichowski promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders AT romanhajek promisingimmunotherapeuticmodalitiesforbcelllymphoproliferativedisorders
_version_	1718432158061690880

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders

Ejemplares similares